Detection of point mutations in the gyrA gene of Helicobacter pylori isolates in Slovenia

Hepato-Gastroenterology

Volumn 56, Issue 91-92, 2009, Pages 925-929

  Kese, Darja ^a   Gubina, Marija ^a   Kogoj, Rok ^a   Strasek, Katja ^a   Tepes, Bojan ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Medical Centre Roga ka   (Slovenia)

Author keywords

Fluoroquinolones; gyrA mutation; Helicobacter pylori; Resistance

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GENOTYPE; HELICOBACTER PYLORI; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SLOVENIA;

ADULT; CIPROFLOXACIN; COHORT STUDIES; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; SLOVENIA;

EID: 67651219455     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Goodwin CS, Armstrong JA: Microbiological aspects of Helicobacter pylori (Campylobacter pylori). Eur J Clin Microbiol 1990; 9:1-13. (Pubitemid 20046729)
2. Taylor DN, Parsonnet J: Epidemiology and natural history of H. pylori infections. In: Blaser MJ, Smith PF, Ravdin J, Greenberg H, Guerrant RL eds. Infections of the gastrointestinal tract New York, 1995, Raven Press.
3. Blaser MJ: Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161:626-633.
4. Graham DY: Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000; 118:S2-8.
5. Gerrits MM, Van Vliet AH, Kuipers EJ, Kusters JG: Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6:699-709. (Pubitemid 44601991)
6. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 1998; 93:386-389. (Pubitemid 29068342)
7. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP: European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20:820-823. (Pubitemid 34020461)
8. Kwon DH, Dore MP, Kim JJ, Kato M, Lee M, Wu JY, Graham DY: High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47:2169-2178. (Pubitemid 36753568)
9. Xia HH, Yu Wong BC, Talley NJ, Lam SK: Alternative and rescue treatment regiments for Helicobacter pylori eradication. Expert Opin Pharamacother 2002; 3:1301-1311. (Pubitemid 34966045)
10. Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R: Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J Med Microbiol 2000; 49:415-418. (Pubitemid 30261405)
11. Sharara AI, Chaar HF, Aoun E, Abdul-Baki H, Araj GF, Kanj SS: Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter 2006; 11:231-236. (Pubitemid 44051348)
12. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ: Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47:3942-3944. (Pubitemid 37485011)
13. Kim JM, Kim JS, Kim N, Jung HC, Song IS: Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005; 56:965-967. (Pubitemid 41631929)
14. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ, Cambau E: Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007; 29:389-396. (Pubitemid 46357606)
15. Glocker E, Stueger HP, Kist M: Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007; 51:346-349. (Pubitemid 46047727)
16. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE: Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995; 39:107-111.
17. Fujimura S, Kato S, Iinuma K, Watanabe A: In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol 2004; 53:1019-1022.
18. NCCLS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard6th ed., M7-A6. National Committee for Clinical Laboratory Standards 2004, Wayne, PA, USA.
19. Megraud F, Lehn N, Lind T, Bayerdorffer E, O'Morain C, Spiller R, Unge P, Van Zanten SV, Wrangstadh M, Burman CF: Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43:2747-2752. (Pubitemid 29519559)
20. Skvarc M, Gubina M, Tepes B: Evaluation of E-test and agar dilution method for testing antibiotic susceptibility of Helicobacter pylori strains to metronidazole and clarithromycin. Int J Antimicrob Agents 2002; 19:S81.
21. Glocker E, Kist M: Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J Clin Microbiol 2004; 42:2241-2246. (Pubitemid 38637854)
22. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS: Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004; 48:4843-4847. (Pubitemid 39577692)
23. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group: Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-587. (Pubitemid 40247914)
24. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C, Goossens H; ESAC Project Group: European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58:423-427. (Pubitemid 44294958)
25. Elseviers MM, Ferech M, Vander Stichele RH, Goossens H; ESAC Project Group: Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf 2007; 16:115-123.
26. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM: Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11:256-280.
27. Nishizawa T, Suzuki H, Umezawa A, Muraoka H, Iwasaki E, Masaoka T, Kobayashi I, Hibi T: Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J Clin Microbiol 2007; 45:303-305. (Pubitemid 46272036)
28. Aim RA, Lin LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, Dejonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ: Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999; 397:176-180. (Pubitemid 29050924)
29. Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust TJ, Hancock RE: Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother 2000; 44:248-254. (Pubitemid 30060714)
30. Wang G, Wilson TJ, Jiang Q, Taylor DE: Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001; 45:727-733. (Pubitemid 32182016)
31. Bogaerts P, Berhin C, Nizet H, Glupczynski Y: Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006; 11:441-445. (Pubitemid 44352615)